	Est. tid*
2027-02-25	08:30	Bokslutskommuniké 2026
2026-08-27	08:30	Kvartalsrapport 2026-Q2
2026-05-19	-	Årsstämma
2026-04-23	-	X-dag ordinarie utdelning PILA 0.00 SEK
2026-02-26	-	Bokslutskommuniké 2025
2025-08-27	-	Kvartalsrapport 2025-Q2
2025-04-30	-	X-dag ordinarie utdelning PILA 0.00 SEK
2025-04-29	-	Årsstämma
2025-02-27	-	Bokslutskommuniké 2024
2024-08-27	-	Kvartalsrapport 2024-Q2
2024-05-17	-	X-dag ordinarie utdelning PILA 0.00 SEK
2024-02-28	-	Bokslutskommuniké 2023
2023-10-25	-	15-10 2023-Q3
2023-08-23	-	Kvartalsrapport 2023-Q2
2023-05-31	-	X-dag ordinarie utdelning PILA 0.00 SEK
2023-05-30	-	Årsstämma
2023-02-28	-	Bokslutskommuniké 2022
2022-10-26	-	Kvartalsrapport 2022-Q3
2022-08-26	-	Kvartalsrapport 2022-Q2
2022-06-08	-	X-dag ordinarie utdelning PILA 0.00 SEK
2022-06-07	-	Årsstämma
2022-04-26	-	Kvartalsrapport 2022-Q1
2022-02-18	-	Bokslutskommuniké 2021

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

PILA PHARMA: CHAIRMAN DORTE X. GRAM REPORT SALE/PURCHASE TRANSACTION BETWEEN OWN CONTROLLED COMPANIES

2026-07-31 11:15:00

PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, announces that a share purchase agreement was made between entities controlled by Dorte X. Gram, Chairman of the Board of PILA PHARMA AB.

On Monday 27 July, a share purchase agreement was made between Xenia Pharma ApS, Denmark, and Gram Equity Invest AB, Sweden, both controlled by Dorte X. Gram.

In the agreement, Xenia Pharma ApS sold it’s 5,000,010 shares in PILA PHARMA AB, to Gram Equity Invest AB that purchased and acquired the shares. The transaction was conducted outside the trading place.
The purchase price for the Shares was DKK 3,976,360 corresponding to SEK 1,18 per share which was the same as the market value on Monday 27 July 2026.

Following the transaction, Dorte X. Gram still directly and indirectly holds a total of 6,303,507 shares corresponding to 13,8% of the shares in PILA PHARMA AB. The transaction has been reported to the Swedish Financial Supervisory Authority (Finansinspektionen) in accordance with applicable regulations.

“Over the summer I decided to gather my indirectly held PILA PHARMA AB shares in a single business unit, to reduce my personal administrative costs and chose Gram Equity Invest AB for the future shareholding. So, this transaction is the formality of me moving my PILA PHARMA AB stockholding in one of my companies to another.”, says Chairman of the Board, Dorte X. Gram

_______

About PILA PHARMA AB (Publ)

PILA PHARMA is a Swedish biotech company based in Malmö, Sweden. The aim of the company is to develop TRPV1 inhibitors as a novel treatment of obesity, type 2 diabetes and potentially of other diseases with an inflammatory background. The Company owns a TRPV1 asset with data and chemical entities including the development candidate XEN-D0501. Further, the Company owns use-patents covering the use of TRPV1-antagonists for treatment of obesity and diabetes and intends to submit further patents regarding the synthesis, formulation, or use of XEN-D0501 or back-up compounds. In July 2022, the Company was awarded orphan drug designation ("ODD") for XEN-D0501 as a treatment for a painful rare disease erythromelalgia. PILA PHARMA currently focuses on obesity and type-2 diabetes whilst also retaining a focus on licensing opportunities for development of the candidate for erythromelalgia and abdominal aorta aneurysm.

About XEN-D0501 and TRPV1 antagonists

XEN-D0501 is a selective, synthetic potent small molecule TRPV1 inhibitor that was in-licensed in 2016. The drug candidate is a small molecule currently formulated in a simple and stable tablet formulation.
TRPV1 inhibitors that down-regulate neurogenic inflammation, has demonstrated applications across pain and inflammatory diseases and potentially plays a role in diabetes and potentially other metabolic disorders like obesity. PILA PHARMA’s founder and current CSO Dorte X. Gram, is the inventor of the principle of treating diabetes and obesity with TRPV1 inhibitors – a discovery-by-surprise during her PhD studies at Novo Nordisk, Denmark. Here she discovered that TRPV1 inhibitors would prevent glucose intolerance and body weight gain in spontaneously obese pre-diabetic rats. These results pointed to a new and previously undiscovered role of TRPV1 in regulating both blood glucose and body weight. Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.
PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by in people living with obesity and type 2 diabetes. Further, in PP-CT02, it was demonstrated that XEN-D0501 (administered as 4 mg bi-daily for 28 days) - with statistical significance versus placebo - enhanced the endogenous insulin response to oral glucose. ANP, a cardiovascular biomarker for heart failure, was also highly statistically significantly reduced.
During 2023 the Company could report very good tolerability of XEN-D0501 following 13 weeks administration of very high doses in 2 animal species, and XEN-D0501 can thus progress into longer clinical trials. A preclinical study in two different rat models of obesity were conducted at the end of 2025 and start of 2026. Initial results showed no effects, but later analyses showed that the used formulation resulted in insufficient exposure, yielding significantly lower levels than anticipated as compared to previously conducted 13-week rat toxicity studies. Given the low exposure observed, the data do not allow for conclusions regarding effect on body weight. The Company will continue its evaluation in clinical trials, where dose and exposure can be adequately controlled.
The next step is now to submit a clinical trial application for a dose-finding study in people living with obesity (PP-CT04). Preparations for submitting clinical trial applications in people living with both obesity and type 2 diabetes (PP-CT03) as well as erythromelalgia (PP-CT05) is also ongoing. The ambition is to create a comprehensive and meaningful data package that supports XEN-D0501 as an oral, potential first-in-class drug candidate.

About obesity and diabetes

Obesity (BMI >30) is pandemic in its essence with estimates of more than 1 billion people living with it in 2025. Overweight (BMI >27) is also at staggeringly high levels with estimates of 4 billion people globally.

It is most often preceding the development of type 2 diabetes and is a serious risk-factor for not only developing type 2 diabetes but also co-morbidities resulting in "whole body dysfunction" and subsequent development of several diseases. The accumulated effect is a year-long reduction in quality of life for obese people with or without diabetes. Obesity leads to an increased risk of developing cardiovascular disease that eventually results in premature death and shortening of life duration. Recent advances and the development of effective antiobesity drugs has proven that pharmacological weight management is possible and leads to obvious quality-oflife and longevity benefits for people living with obesity. Even long-term, public health costs are expected to be reduced if the clinically negative effects of the obesity pandemic are limited. This has sparked a general interest in future potential oral treatments that can meet the accessibility criteria needed to stimulate enormous and growing demand.

Diabetes is a similar spanning pandemic with strong ties to obesity, and with a staggering estimated prevalence of more than 828 million people living with diabetes corresponding to approximately 8-10% of the global adult population. Among these, its estimated that more than approximately 90% of all diabetics suffer from type-2 diabetes, whilst approximately less than 10% suffers from type-1 diabetes. Despite recent therapeutic advances, large and growing unmet needs exist both from efficacy, safety, and accessibility standpoints.

About erythromelalgia

Erythromelalgia is a rare disease where neurogenic inflammation plays a role in the development of symptoms. The disease can cause near-constant or episodic pain (ranging from mild tingling to severe burning sensations), and redness to extremities. It most commonly affects the feet but may also occur in the hands, face, or other parts of the body with both nerves and blood vessels involved. Symptoms are frequently managed through avoidance of pain triggers. The disorder can be extremely debilitating, with a significant negative impact on quality of life and with potential to impact mortality rates among young people and the suicide rates among adults. There are no current treatments available to patients, but it is widely believed by doctors that an oral solution with systemic effects would be highly preferable.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode